



100-126 GPT803 pt fee

DOCKET NO.: ISIS-0710

PATENT #15

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

COOK, MCGEE AND GUINOSSO

Serial No.: 07/967,267

Group No.: 1803

MAR 30 1995 GROUP 1803

Filed: OCTOBER 27, 1992

Examiner: G. KUNZ

For: OLIGONUCLEOTIDES CONTAINING 2'-O-MODIFIED PURINES

I, Paul K. Legaard, Registration No. 38,534 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

On March 10, 1995

Paul K. Legaard Reg. No. 38,534

Commissioner of Patents & Trademarks
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- () In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

(XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below.

(XX) The fee of \$200.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

(xx) Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in triplicate.

The relevance of those listed references which are not in the English language is as follows:

German Patent DE 3915462 relates to a method for making 2'-O-substituted-5-O-dimethoxytritylguanosine phosphoramidites. The examples describe 2'-O-methyl, 2'-O-allyl, and 2'-O-(2-nitrobenzyl) structures. No Gap structures are disclosed. An English abstract is attached to this reference.


EPO Patent 0399330 relates to 2'-O-substituents and conjugate groups extending from the phosphate group. No Gap structures are disclosed. An English abstract is attached to this reference. Applicants believe that this reference is related to Canadian Patent 2,017,369, which is enclosed herewith.

German Patent DE 4110085 relates to 2'-O-alkyl (C₁-C₃₀). There is no description of Gap type structures. An English abstract is attached to this reference.

EPO Patent 0519463 relates to straight chain and branched oligonucleotides. There is no description of Gap type structures.

Respectfully submitted,

Date: March 10, 1995


Paul K. Legaard
Registration No. 38,534

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100